We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 18, 2020

Gefitinib Plus Durvalumab in EGFR TKI–Naïve Patients With EGFR Mutation–Positive Locally Advanced/Metastatic NSCLC

British Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
A Phase 1 Study of Gefitinib Combined With Durvalumab in EGFR TKI-Naive Patients With EGFR Mutation-Positive Locally Advanced/Metastatic Non-Small-Cell Lung Cancer
Br. J. Cancer 2020 Oct 05;[EPub Ahead of Print], BC Creelan, TC Yeh, SW Kim, N Nogami, DW Kim, LQM Chow, S Kanda, R Taylor, W Tang, M Tang, HK Angell, MP Roudier, M Marotti, DL Gibbons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading